#PharmaTimes #pharma #pharmaceuticals #oncology #NICE #NICErecommended #MSD #pembrolizumab #KEYTRUDA #cervicalcancer #locallyadvancedcervicalcancer #immunotherapy #LACC #phase3 #KEYNOTEA18trial #progressionfreesurvival #overallsurvival #cervicalcancerpatients #ClinicalOncology
zurl.co/lDVmm
zurl.co/lDVmm
NICE recommends MSD’s pembrolizumab for locally advanced cervical cancer - PharmaTimes
First immunotherapy approved for LACC in England offers new treatment option for women
pharmatimes.com
June 26, 2026 at 8:57 AM
This retrospective study reveals that #ThoracicRadiotherapy (RT) can significantly delay the development of resistance to 3GEGFR-TKIs and prolong #progressionfreesurvival (PFS) in advanced #NonSmallCellLungCancer (NSCLC) patients.
Read more: link.springer.com/article/10.1...
Read more: link.springer.com/article/10.1...
June 5, 2025 at 9:30 PM
This retrospective study reveals that #ThoracicRadiotherapy (RT) can significantly delay the development of resistance to 3GEGFR-TKIs and prolong #progressionfreesurvival (PFS) in advanced #NonSmallCellLungCancer (NSCLC) patients.
Read more: link.springer.com/article/10.1...
Read more: link.springer.com/article/10.1...
#Haematology #Oncology #Scotland #NHSScotland #multiplemyeloma #GSK #Blenrep #belantamabmafodotin #Blenrepcombination #lenalidomide #ScottishMedicinesConsortium #SMC #bortezomibanddexamethasone #BVd #SMCrecommendation #phase3data #DREAMM7study #progressionfreesurvival
zurl.co/ydmDa
zurl.co/ydmDa
Scotland approves new treatment option for multiple myeloma patients - PharmaTimes
Blenrep combination offers improved survival for those ineligible for lenalidomide
pharmatimes.com
October 15, 2025 at 9:02 AM
Scientists show that #ICEUS improves #ResidualTumor detection during malignant #glioma surgery and is linked to better overall and #ProgressionFreeSurvival, highlighting ICEUS as a #prognosticfactor and tool to enhance surgical outcomes.
Read: doi.org/10.1007/s115...
Read: doi.org/10.1007/s115...
January 23, 2026 at 2:45 AM
Scientists show that #ICEUS improves #ResidualTumor detection during malignant #glioma surgery and is linked to better overall and #ProgressionFreeSurvival, highlighting ICEUS as a #prognosticfactor and tool to enhance surgical outcomes.
Read: doi.org/10.1007/s115...
Read: doi.org/10.1007/s115...
#PierreFabre #ECapproval #Braftovi #encorafenib #colorectalcancer #BRAFV600EmutantmCRC #metastaticcolorectalcancer #mCRC #combinationtherapy #cetuximab #FOLFOX #phase3 #Breakwatertrial #progressionfreesurvival #primaryendpoint #overallsurvivalbenefit #LaboratoiresPierreFabre
zurl.co/7jFHW
zurl.co/7jFHW
Pierre Fabre wins EC approval for Braftovi regimen in BRAFV600E‑mutant mCRC - PharmaTimes
Breakwater phase 3 data show significant gains in progression‑free survival
pharmatimes.com
June 24, 2026 at 8:48 AM
#PierreFabreLaboratories #PierreFabre #CHMP #BRAFTOVI #BRAFV600Emutantmetastaticcolorectalcancer #colorectalcancer #EuropeanMedicinesAgency #EMA #encorafenib #combinationtherapy #cetuximab #FOLFOX #BREAKWATERtrial #oxaliplatinbasedchemotherapy #progressionfreesurvival
zurl.co/dN5b9
zurl.co/dN5b9
Pierre Fabre Laboratories secures CHMP backing for first‑line BRAFTOVI regimen - PharmaTimes
Data shows survival benefit in BRAFV600E‑mutant metastatic colorectal cancer
pharmatimes.com
May 27, 2026 at 9:49 AM
Webinar: Philip He (Early phase statistics, Daiichi Sankyo) will talk about: Ensuring Quality and Interpretability of PFS and OS in Oncology Clinical Trials
🗓 Date & Time: Friday, Jan 16th, 2026
08:00 – 09:00 AM (PDT)
Zoom link in this post:
www.linkedin.com/posts/yi-pan...
🗓 Date & Time: Friday, Jan 16th, 2026
08:00 – 09:00 AM (PDT)
Zoom link in this post:
www.linkedin.com/posts/yi-pan...
#dahshu #idswg #kolseminar #oncologyclinicaltrials #clinicaltrialdesign #progressionfreesurvival #overallsurvival #estimands #iche9r1 #oncologystatistics #biostatistics #regulatoryscience… | Yi Pan
✨ Jan 2026 DahShu IDSWG KOL Seminar ✨
We are honored to welcome Dr. Philip He as our distinguished speaker!
📘 Title: Ensuring Quality and Interpretability of Progression Free Survival and Overall ...
www.linkedin.com
December 30, 2025 at 1:34 PM
Webinar: Philip He (Early phase statistics, Daiichi Sankyo) will talk about: Ensuring Quality and Interpretability of PFS and OS in Oncology Clinical Trials
🗓 Date & Time: Friday, Jan 16th, 2026
08:00 – 09:00 AM (PDT)
Zoom link in this post:
www.linkedin.com/posts/yi-pan...
🗓 Date & Time: Friday, Jan 16th, 2026
08:00 – 09:00 AM (PDT)
Zoom link in this post:
www.linkedin.com/posts/yi-pan...
A unique #InvestigationalDrug formulation more than doubled the median #survival and #ProgressionFreeSurvival times of #glioblastoma patients without causing dose-limiting toxic effects.
#BrainCancer
#BrainCancer
Investigational drug more than doubles survival time for glioblastoma patients – BioNews Central
A unique investigational drug formulation more than doubled the median survival and progression-free survival times of glioblastoma patients without causing dose-limiting toxic effects. ...
sbee.link
March 8, 2025 at 2:42 AM
A unique #InvestigationalDrug formulation more than doubled the median #survival and #ProgressionFreeSurvival times of #glioblastoma patients without causing dose-limiting toxic effects.
#BrainCancer
#BrainCancer
#Culmerciclib combined with #fulvestrant significantly improved #ProgressionFreeSurvival and response rate in pretreated HR‑positive, #HER2‑negative advanced #BreastCancer, supporting combined CDK2/4/6 blockade as a promising therapeutic strategy.
#STTT: doi.org/10.1038/s413...
#STTT: doi.org/10.1038/s413...
January 19, 2026 at 8:00 PM
#Culmerciclib combined with #fulvestrant significantly improved #ProgressionFreeSurvival and response rate in pretreated HR‑positive, #HER2‑negative advanced #BreastCancer, supporting combined CDK2/4/6 blockade as a promising therapeutic strategy.
#STTT: doi.org/10.1038/s413...
#STTT: doi.org/10.1038/s413...
This phase 3 trial shows that cetuximab β plus #FOLFIRI significantly improves #ProgressionFreeSurvival, overall survival, and response rates compared to FOLFIRI alone in RAS/BRAF wild-type #MetastaticColorectalCancer with manageable toxicity.
#STTT:
#STTT:
First-line treatment of anti-EGFR monoclonal antibody cetuximab β plus FOLFIRI versus FOLFIRI alone in Chinese patients with RAS/BRAF wild-type metastatic colorectal cancer: a randomized, phase 3 trial - Signal Transduction and Targeted Therapy
Signal Transduction and Targeted Therapy - First-line treatment of anti-EGFR monoclonal antibody cetuximab β plus FOLFIRI versus FOLFIRI alone in Chinese patients with RAS/BRAF wild-type...
doi.org
January 2, 2026 at 2:50 PM
This phase 3 trial shows that cetuximab β plus #FOLFIRI significantly improves #ProgressionFreeSurvival, overall survival, and response rates compared to FOLFIRI alone in RAS/BRAF wild-type #MetastaticColorectalCancer with manageable toxicity.
#STTT:
#STTT:
This phase Ib/II trial reports that the NASCA regimen achieved higher ORR and longer #ProgressionFreeSurvival than nab‑paclitaxel/gemcitabine, with manageable safety, highlighting its promise for treating advanced #PancreaticDuctalAdenocarcinoma.
#STTT: doi.org/10.1038/s413...
#STTT: doi.org/10.1038/s413...
First-line treatment with chemotherapy, surufatinib (an angio-immuno kinase inhibitor), and camrelizumab (an anti-PD-1 antibody) for locally advanced or metastatic pancreatic ductal adenocarcinoma: a phase Ib/II randomized study - Signal Transduction and Targeted Therapy
Signal Transduction and Targeted Therapy - First-line treatment with chemotherapy, surufatinib (an angio-immuno kinase inhibitor), and camrelizumab (an anti-PD-1 antibody) for locally advanced or...
doi.org
December 31, 2025 at 1:01 PM
This phase Ib/II trial reports that the NASCA regimen achieved higher ORR and longer #ProgressionFreeSurvival than nab‑paclitaxel/gemcitabine, with manageable safety, highlighting its promise for treating advanced #PancreaticDuctalAdenocarcinoma.
#STTT: doi.org/10.1038/s413...
#STTT: doi.org/10.1038/s413...
This phase III trial demonstrates that #ARX788 significantly improves #ProgressionFreeSurvival over lapatinib plus capecitabine in #HER2-positive advanced #BreastCancer, showing strong efficacy and manageable ocular and #PulmonaryToxicity.
#OpenAccess #STTT: doi.org/10.1038/s413...
#OpenAccess #STTT: doi.org/10.1038/s413...
November 13, 2025 at 10:00 AM
This phase III trial demonstrates that #ARX788 significantly improves #ProgressionFreeSurvival over lapatinib plus capecitabine in #HER2-positive advanced #BreastCancer, showing strong efficacy and manageable ocular and #PulmonaryToxicity.
#OpenAccess #STTT: doi.org/10.1038/s413...
#OpenAccess #STTT: doi.org/10.1038/s413...
The NASCA regimen—surufatinib, #camrelizumab, nab-paclitaxel, and S-1—achieved superior response and #progressionfreesurvival in #metastatic #PancreaticDuctalAdenocarcinoma, with immune and #biomarker profiling predicting improved outcomes. #medsky
#STTT: doi.org/10.1038/s413...
#STTT: doi.org/10.1038/s413...
October 17, 2025 at 1:31 PM
The NASCA regimen—surufatinib, #camrelizumab, nab-paclitaxel, and S-1—achieved superior response and #progressionfreesurvival in #metastatic #PancreaticDuctalAdenocarcinoma, with immune and #biomarker profiling predicting improved outcomes. #medsky
#STTT: doi.org/10.1038/s413...
#STTT: doi.org/10.1038/s413...